vertex pharmaceuticals - Search News

Vertex, FDA

Hosted on MSN · 50m

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

MarketWatch · 3h

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

FiercePharma · 11h

Vertex scores FDA nod for long-awaited non-opioid pain reliever Journavx

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation in pain relief in more than two decades.

vertex pharmaceuticals, England and Sickle Cell Disease

Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the U.K. and Vertex.

Business Insider · 5h

Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with

The Bakersfield Californian · 5h

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY ® (exagamglogene autotemcel).

13mon MSN

These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More

Wall Street also was waiting to see whether President Donald Trump would follow through on his pledge to enact tariffs on ...

33m

Truist Financial Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Truist Financial analyst Joon Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s shares closed ...

5don MSN

Is Vertex Pharmaceuticals Stock a Buy in 2025?

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

1h

Vertex Pharmaceuticals’ JOURNA VX: Navigating Market Challenges Despite Promising Financial Outlook

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.Invest with Confidence: Follow ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results